Health Trials

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

ConditionsCervical CancerCervical Cancer MetastaticCervical Cancer RecurrentCervical AdenocarcinomaCervical Cancer Squamous Cell
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorTianjin Medical University Cancer Institute and Hospital

About this trial

To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.

Eligibility criteria

Qualifiers

Patients with recurrent/metastatic cervical cancer who previously experienced failure of PD-1 blockade therapy;

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

Life expectancy ≥3 months;

Absolute neutrophil count (ANC) ≥1.0×10⁹/L

Disqualifiers

Prior treatment with anti-PD-1/CTLA-4 bispecific antibodies;

Active autoimmune disease requiring systemic control with corticosteroids (≥10 mg/day prednisone equivalent) or immunosuppressants within 14 days prior to enrollment;

Acute myocardial infarction

Unstable angina

Trial design

Treatments tested in this trial

  • QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

Treatment groups

50 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Tianjin Medical University Cancer Institute and Hospital

Lead sponsor

Source ClinicalTrials.gov